FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225105825> ?p ?o ?g. }

• W4225105825 endingPage "1142" @default.
• W4225105825 startingPage "1136" @default.
• W4225105825 abstract "Objectives Iberdomide is a high-affinity cereblon ligand that promotes proteasomal degradation of transcription factors Ikaros ( IKZF1 ) and Aiolos ( IKZF3 ). Pharmacodynamics and pharmacokinetics of oral iberdomide were evaluated in a phase 2b study of patients with active systemic lupus erythematosus (SLE). Methods Adults with autoantibody-positive SLE were randomised to placebo (n=83) or once daily iberdomide 0.15 mg (n=42), 0.3 mg (n=82) or 0.45 mg (n=81). Pharmacodynamic changes in whole blood leucocytes were measured by flow cytometry, regulatory T cells (Tregs) by epigenetic assay, plasma cytokines by ultrasensitive cytokine assay and gene expression by Modular Immune Profiling. Results Iberdomide exhibited linear pharmacokinetics and dose-dependently modulated leucocytes and cytokines. Compared with placebo at week 24, iberdomide 0.45 mg significantly (p<0.001) reduced B cells, including those expressing CD268 (TNFRSF13C) (−58.3%), and plasmacytoid dendritic cells (−73.9%), and increased Tregs (+104.9%) and interleukin 2 (IL-2) (+144.1%). Clinical efficacy was previously reported in patients with high IKZF3 expression and high type I interferon (IFN) signature at baseline and confirmed here in those with an especially high IFN signature. Iberdomide decreased the type I IFN gene signature only in patients with high expression at baseline (−81.5%; p<0.001) but decreased other gene signatures in all patients. Conclusion Iberdomide significantly reduced activity of type I IFN and B cell pathways, and increased IL-2 and Tregs, suggesting a selective rebalancing of immune abnormalities in SLE. Clinical efficacy corresponded to reduction of the type I IFN gene signature. Trial registration number NCT03161483 ." @default.
• W4225105825 created "2022-04-30" @default.
• W4225105825 creator A5002362140 @default.
• W4225105825 creator A5006303399 @default.
• W4225105825 creator A5010291947 @default.
• W4225105825 creator A5012549811 @default.
• W4225105825 creator A5015092934 @default.
• W4225105825 creator A5015668076 @default.
• W4225105825 creator A5017572254 @default.
• W4225105825 creator A5021355807 @default.
• W4225105825 creator A5023265561 @default.
• W4225105825 creator A5025955879 @default.
• W4225105825 creator A5028098177 @default.
• W4225105825 creator A5029793095 @default.
• W4225105825 creator A5034905722 @default.
• W4225105825 creator A5043874873 @default.
• W4225105825 creator A5048813974 @default.
• W4225105825 creator A5052053321 @default.
• W4225105825 creator A5063154015 @default.
• W4225105825 creator A5069066722 @default.
• W4225105825 creator A5070545356 @default.
• W4225105825 creator A5071050551 @default.
• W4225105825 creator A5076651506 @default.
• W4225105825 creator A5086942556 @default.
• W4225105825 date "2022-04-27" @default.
• W4225105825 modified "2023-10-15" @default.
• W4225105825 title "Biological impact of iberdomide in patients with active systemic lupus erythematosus" @default.
• W4225105825 cites W1795880523 @default.
• W4225105825 cites W1965672602 @default.
• W4225105825 cites W1971833707 @default.
• W4225105825 cites W1998298742 @default.
• W4225105825 cites W2036209857 @default.
• W4225105825 cites W2039378822 @default.
• W4225105825 cites W2053841483 @default.
• W4225105825 cites W2103056503 @default.
• W4225105825 cites W2128304063 @default.
• W4225105825 cites W2135199713 @default.
• W4225105825 cites W2140296331 @default.
• W4225105825 cites W2167501252 @default.
• W4225105825 cites W2170293791 @default.
• W4225105825 cites W2486559230 @default.
• W4225105825 cites W2556359407 @default.
• W4225105825 cites W2585846175 @default.
• W4225105825 cites W2606131188 @default.
• W4225105825 cites W2732476823 @default.
• W4225105825 cites W2752652435 @default.
• W4225105825 cites W2885215095 @default.
• W4225105825 cites W2891364583 @default.
• W4225105825 cites W2946619429 @default.
• W4225105825 cites W2982474992 @default.
• W4225105825 cites W2986363545 @default.
• W4225105825 cites W3047319477 @default.
• W4225105825 cites W3089045575 @default.
• W4225105825 cites W3101971981 @default.
• W4225105825 cites W3126997388 @default.
• W4225105825 cites W4220810697 @default.
• W4225105825 doi "https://doi.org/10.1136/annrheumdis-2022-222212" @default.
• W4225105825 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35477518" @default.
• W4225105825 hasPublicationYear "2022" @default.
• W4225105825 type Work @default.
• W4225105825 citedByCount "9" @default.
• W4225105825 countsByYear W42251058252022 @default.
• W4225105825 countsByYear W42251058252023 @default.
• W4225105825 crossrefType "journal-article" @default.
• W4225105825 hasAuthorship W4225105825A5002362140 @default.
• W4225105825 hasAuthorship W4225105825A5006303399 @default.
• W4225105825 hasAuthorship W4225105825A5010291947 @default.
• W4225105825 hasAuthorship W4225105825A5012549811 @default.
• W4225105825 hasAuthorship W4225105825A5015092934 @default.
• W4225105825 hasAuthorship W4225105825A5015668076 @default.
• W4225105825 hasAuthorship W4225105825A5017572254 @default.
• W4225105825 hasAuthorship W4225105825A5021355807 @default.
• W4225105825 hasAuthorship W4225105825A5023265561 @default.
• W4225105825 hasAuthorship W4225105825A5025955879 @default.
• W4225105825 hasAuthorship W4225105825A5028098177 @default.
• W4225105825 hasAuthorship W4225105825A5029793095 @default.
• W4225105825 hasAuthorship W4225105825A5034905722 @default.
• W4225105825 hasAuthorship W4225105825A5043874873 @default.
• W4225105825 hasAuthorship W4225105825A5048813974 @default.
• W4225105825 hasAuthorship W4225105825A5052053321 @default.
• W4225105825 hasAuthorship W4225105825A5063154015 @default.
• W4225105825 hasAuthorship W4225105825A5069066722 @default.
• W4225105825 hasAuthorship W4225105825A5070545356 @default.
• W4225105825 hasAuthorship W4225105825A5071050551 @default.
• W4225105825 hasAuthorship W4225105825A5076651506 @default.
• W4225105825 hasAuthorship W4225105825A5086942556 @default.
• W4225105825 hasBestOaLocation W42251058251 @default.
• W4225105825 hasConcept C111113717 @default.
• W4225105825 hasConcept C112705442 @default.
• W4225105825 hasConcept C126322002 @default.
• W4225105825 hasConcept C159654299 @default.
• W4225105825 hasConcept C163764329 @default.
• W4225105825 hasConcept C170286685 @default.
• W4225105825 hasConcept C203014093 @default.
• W4225105825 hasConcept C2776090121 @default.
• W4225105825 hasConcept C2776912625 @default.
• W4225105825 hasConcept C2778453870 @default.
• W4225105825 hasConcept C2778690821 @default.

• next